ACET Aceto Corporation

ACETO LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Aceto Corporation to Contact the Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aceto Corporation (“Aceto” or the “Company”) (NASDAQ:ACET) of the June 25, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Aceto stock or options between August 25, 2017 and April 18, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/ACET. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

The lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all those who purchased Aceto securities between August 25, 2017 and April 18, 2018 (the “Class Period”). The case, Mulligan v. Aceto Corporation et al., No. 2:18-cv-02425 was filed on April 24, 2018 and has been assigned to Judge Joseph F. Bianco.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Company would incur large non-cash intangible asset impairment charges; (ii) the Company lacked effective internal control over financial reporting; (iii) the Company’s fiscal 2018 financial guidance was overstated; and, (iv) as a result of the foregoing, Aceto’s public statements were materially false and misleading at all relevant time.

Specifically, on April 18, 2018, after market close, Aceto issued a press release, also attached as exhibit 99.1 to the Form 8-K filed with the Securities Exchange Commission (‘SEC”), announcing, “in light of the persistent adverse conditions in the generics market, it is negotiating with its bank lenders a waiver of its credit agreement with respect to its total net leverage and debt service coverage financial covenants in the fiscal third quarter, and that the financial guidance issued on February 1, 2018, should no longer be relied upon. In addition, the Company anticipates recording non-cash intangible asset impairment charges, including goodwill, in the range of $230 million to $260 million on certain currently marketed and pipeline generic products as a result of continued intense competitive and pricing pressures.”

After the announcement, Aceto’s share price fell from $7.40 per share on April 18, 2018 to a closing price of $2.66 on April 19, 2018—a $4.74 or a 64.0541% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Aceto’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

EN
27/04/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aceto Corporation

MarketLine Department
  • MarketLine Department

Disproquima SA - Company Profile and SWOT Analysis

Summary Disproquima SA - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Disproquima SA (Disproquima) is a marketer and distributor of wide range of functional ingredients. The company's product portfolio includes active pharmaceutical ingredients, vitamins and minerals, anti...

Adicet Bio Inc: 2 directors

A director at Adicet Bio Inc bought 5,000 shares at 2.400USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

ACETO Completes the Sale of Its Chemicals Business Assets

ACETO Completes the Sale of Its Chemicals Business Assets PORT WASHINGTON, N.Y., April 30, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ) announced today that it has completed the previously disclosed sale of its chemicals business assets to an affiliate of New Mountain Capital, a leading growth-oriented investment firm with over $20 billion in assets under management. The purchase price paid in the transaction consisted of cash plus the payment of cure costs and the assumption of certain liabilities.  ACETO used a portion of the proceeds from the transaction to repay 100% of ...

 PRESS RELEASE

ACETO to Sell its Chemicals Business Assets to New Mountain Capital

ACETO to Sell its Chemicals Business Assets to New Mountain Capital PORT WASHINGTON, N.Y., April 15, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has agreed to sell its chemicals business assets to an affiliate of New Mountain Capital (“NMC”), a leading growth-oriented investment firm with over $20 billion in assets under management. The asset purchase agreement was entered into following ...

 PRESS RELEASE

ACETO Receives Court Approval of “Stalking Horse” Agreement to Sel...

ACETO Receives Court Approval of “Stalking Horse” Agreement to Sell Rising Pharmaceuticals to Shore Suven Pharma, Inc. PORT WASHINGTON, N.Y., April 12, 2019 (GLOBE NEWSWIRE) -- ACETO Corporation (OTC: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has received approval from the U.S. Bankruptcy Court  to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries to Shore Suven Pharma, Inc. for gross cash proceeds of $15 million, plu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch